Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a.

MacMillan EL, Schubert JJ, Vavasour IM, Tam R, Rauscher A, Taylor C, White R, Garren H, Clayton D, Levesque V, Li DK, Kolind SH, Traboulsee AL.

Mult Scler J Exp Transl Clin. 2019 Oct 15;5(4):2055217319879952. doi: 10.1177/2055217319879952. eCollection 2019 Oct-Dec.

2.

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.

Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS, Buffels R, Fiore D, Garren H, Han J, Hauser SL.

J Neurol. 2019 May;266(5):1182-1193. doi: 10.1007/s00415-019-09248-6. Epub 2019 Feb 28.

3.

Advanced imaging findings in progressive solitary sclerosis: a single lesion or a global disease?

Lee LE, Chan JK, Nevill E, Soares A, Vavasour IM, MacMillan EL, Garren H, Clayton D, Keegan BM, Tam R, Traboulsee AL, Kolind SH, Carruthers RL.

Mult Scler J Exp Transl Clin. 2019 Jan 16;5(1):2055217318824612. doi: 10.1177/2055217318824612. eCollection 2019 Jan-Mar.

4.

Quantitative neuroimaging measures of myelin in the healthy brain and in multiple sclerosis.

O'Muircheartaigh J, Vavasour I, Ljungberg E, Li DKB, Rauscher A, Levesque V, Garren H, Clayton D, Tam R, Traboulsee A, Kolind S.

Hum Brain Mapp. 2019 May;40(7):2104-2116. doi: 10.1002/hbm.24510. Epub 2019 Jan 15.

5.

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.

Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L.

Ann Neurol. 2018 Oct;84(4):527-536. doi: 10.1002/ana.25313.

6.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G.

Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.

7.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

8.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

9.

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.

Havrdová E, Belova A, Goloborodko A, Tisserant A, Wright A, Wallstroem E, Garren H, Maguire RP, Johns DR.

J Neurol. 2016 Jul;263(7):1287-95. doi: 10.1007/s00415-016-8128-x. Epub 2016 May 3.

PMID:
27142710
10.

Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8⁺ T cells in type 1 diabetes.

Roep BO, Solvason N, Gottlieb PA, Abreu JRF, Harrison LC, Eisenbarth GS, Yu L, Leviten M, Hagopian WA, Buse JB, von Herrath M, Quan J, King RS, Robinson WH, Utz PJ, Garren H; BHT-3021 Investigators, Steinman L.

Sci Transl Med. 2013 Jun 26;5(191):191ra82. doi: 10.1126/scitranslmed.3006103.

11.

Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice.

Sarikonda G, Sachithanantham S, Manenkova Y, Kupfer T, Posgai A, Wasserfall C, Bernstein P, Straub L, Pagni PP, Schneider D, Calvo TR, Coulombe M, Herold K, Gill RG, Atkinson M, Nepom G, Ehlers M, Staeva T, Garren H, Steinman L, Chan AC, von Herrath M.

PLoS One. 2013;8(2):e54712. doi: 10.1371/journal.pone.0054712. Epub 2013 Feb 6.

12.

Evolution of MS lesions to black holes under DNA vaccine treatment.

Papadopoulou A, von Felten S, Traud S, Rahman A, Quan J, King R, Garren H, Steinman L, Cutter G, Kappos L, Radue EW.

J Neurol. 2012 Jul;259(7):1375-82. doi: 10.1007/s00415-011-6361-x. Epub 2012 Jan 6.

PMID:
22222856
14.
15.

Multiple sclerosis therapies: molecular mechanisms and future.

Fontoura P, Garren H.

Results Probl Cell Differ. 2010;51:259-85. doi: 10.1007/400_2010_36. Review.

PMID:
20838962
16.

DNA vaccines for autoimmune diseases.

Garren H.

Expert Rev Vaccines. 2009 Sep;8(9):1195-203. doi: 10.1586/erv.09.83. Review.

PMID:
19722893
17.

Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites.

Solvason N, Lou YP, Peters W, Evans E, Martinez J, Ramirez U, Ocampo A, Yun R, Ahmad S, Liu E, Yu L, Eisenbarth G, Leviten M, Steinman L, Garren H.

J Immunol. 2008 Dec 15;181(12):8298-307.

18.

A DNA vaccine for multiple sclerosis.

Garren H.

Expert Opin Biol Ther. 2008 Oct;8(10):1539-50. doi: 10.1517/14712598.8.10.1539 . Review.

PMID:
18774921
19.

Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.

Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L; BHT-3009 Study Group.

Ann Neurol. 2008 May;63(5):611-20. doi: 10.1002/ana.21370.

PMID:
18481290
20.

Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.

Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H.

Arch Neurol. 2007 Oct;64(10):1407-15. Epub 2007 Aug 13.

PMID:
17698695
21.

Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.

Fontoura P, Garren H, Steinman L.

Int Rev Immunol. 2005 Sep-Dec;24(5-6):415-46. Review.

PMID:
16318989
22.

Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite.

Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L.

Science. 2005 Nov 4;310(5749):850-5. Erratum in: Science. 2006 Feb 17;311(5763):954.

23.

A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease.

Ho PP, Fontoura P, Platten M, Sobel RA, DeVoss JJ, Lee LY, Kidd BA, Tomooka BH, Capers J, Agrawal A, Gupta R, Zernik J, Yee MK, Lee BJ, Garren H, Robinson WH, Steinman L.

J Immunol. 2005 Nov 1;175(9):6226-34.

24.

Immunity to the extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitis.

Fontoura P, Ho PP, DeVoss J, Zheng B, Lee BJ, Kidd BA, Garren H, Sobel RA, Robinson WH, Tessier-Lavigne M, Steinman L.

J Immunol. 2004 Dec 1;173(11):6981-92.

25.

An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems.

Ho PP, Fontoura P, Ruiz PJ, Steinman L, Garren H.

J Immunol. 2003 Nov 1;171(9):4920-6.

26.

Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis.

Robinson WH, Fontoura P, Lee BJ, de Vegvar HE, Tom J, Pedotti R, DiGennaro CD, Mitchell DJ, Fong D, Ho PP, Ruiz PJ, Maverakis E, Stevens DB, Bernard CC, Martin R, Kuchroo VK, van Noort JM, Genain CP, Amor S, Olsson T, Utz PJ, Garren H, Steinman L.

Nat Biotechnol. 2003 Sep;21(9):1033-9. Epub 2003 Aug 10.

PMID:
12910246
27.

Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination.

Pedotti R, DeVoss JJ, Youssef S, Mitchell D, Wedemeyer J, Madanat R, Garren H, Fontoura P, Tsai M, Galli SJ, Sobel RA, Steinman L.

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1867-72. Epub 2003 Feb 7.

28.
29.

Millennium Award. Proteomics for the development of DNA tolerizing vaccines to treat autoimmune disease.

Robinson WH, Garren H, Utz PJ, Steinman L.

Clin Immunol. 2002 Apr;103(1):7-12. Review.

PMID:
11987980
30.

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis.

Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L.

Nat Med. 2002 May;8(5):500-8.

PMID:
11984595
31.

DNA vaccination in the treatment of autoimmune disease.

Garren H, Steinman L.

Curr Dir Autoimmun. 2000;2:203-16. Review. No abstract available.

PMID:
11791457
32.

Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway.

Garren H, Ruiz PJ, Watkins TA, Fontoura P, Nguyen LT, Estline ER, Hirschberg DL, Steinman L.

Immunity. 2001 Jul;15(1):15-22.

33.

Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice.

Urbanek-Ruiz I, Ruiz PJ, Paragas V, Garren H, Steinman L, Fathman CG.

Clin Immunol. 2001 Aug;100(2):164-71.

PMID:
11465945
34.

Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.

Karpuj MV, Garren H, Slunt H, Price DL, Gusella J, Becher MW, Steinman L.

Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7388-93.

35.

Microbial epitopes act as altered peptide ligands to prevent experimental autoimmune encephalomyelitis.

Ruiz PJ, Garren H, Hirschberg DL, Langer-Gould AM, Levite M, Karpuj MV, Southwood S, Sette A, Conlon P, Steinman L.

J Exp Med. 1999 Apr 19;189(8):1275-84.

36.

Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation.

Ruiz PJ, Garren H, Ruiz IU, Hirschberg DL, Nguyen LV, Karpuj MV, Cooper MT, Mitchell DJ, Fathman CG, Steinman L.

J Immunol. 1999 Mar 15;162(6):3336-41.

37.

Idiotypic immunization induces immunity to mutated p53 and tumor rejection.

Ruiz PJ, Wolkowicz R, Waisman A, Hirschberg DL, Carmi P, Erez N, Garren H, Herkel J, Karpuj M, Steinman L, Rotter V, Cohen IR.

Nat Med. 1998 Jun;4(6):710-2.

PMID:
9623981
38.

The specificity of the antibody response in multiple sclerosis.

Garren H, Steinman L, Lock C.

Ann Neurol. 1998 Jan;43(1):4-6. Review. No abstract available.

PMID:
9450762
39.

The Drosophila sine oculis locus encodes a homeodomain-containing protein required for the development of the entire visual system.

Cheyette BN, Green PJ, Martin K, Garren H, Hartenstein V, Zipursky SL.

Neuron. 1994 May;12(5):977-96.

PMID:
7910468
40.

The Drosophila anachronism locus: a glycoprotein secreted by glia inhibits neuroblast proliferation.

Ebens AJ, Garren H, Cheyette BN, Zipursky SL.

Cell. 1993 Jul 16;74(1):15-27.

PMID:
7916657
41.
42.

An investigation of the resistance of white leghorn chicks to Salmonella gallinarum.

Prince WR, Garren HW.

Poult Sci. 1966 Nov;45(6):1149-53. No abstract available.

PMID:
5972250
43.

Differentiation between a growth-promoting factor and a tumour-susceptibility factor in eggs.

HILL CH, GARREN HW.

Nature. 1959 Sep 12;184(Suppl 11):824-5. No abstract available.

PMID:
13852348
44.

Attempt to stimulate lymphatic gland changes of fowl typhoid with adrenal cortex extract.

GARREN HW.

Proc Soc Exp Biol Med. 1957 Aug-Sep;95(4):716-9. No abstract available.

PMID:
13465781
45.

The influence of choline on the transplantation of a lymphoid tumor (RPL-12) into chicks.

GARREN HW, HILL CH.

Cancer Res. 1956 Dec;16(11):1019-22. No abstract available.

46.

Effect of genistin on growth and development of the male mouse.

MATRONE G, SMART WW Jr, CARTER MW, SMART VW, GARREN HW.

J Nutr. 1956 Jun 10;59(2):235-41. No abstract available.

PMID:
13346413
47.

The effect of high levels of vitamins on the resistance of chicks to fowl typhoid.

HILL CH, GARREN HW.

Ann N Y Acad Sci. 1955 Oct 28;63(2):186-94. No abstract available.

PMID:
13340620
48.

Influence of high levels of vitamins on resistance of chicks to fowl typhoid.

HILL CH, GARREN HW, KELLY JW, BARBER CW.

Proc Soc Exp Biol Med. 1955 Apr;88(4):535-7. No abstract available.

PMID:
14371690
49.

Heat load and voluntary tolerance time.

CRAIG FN, GARREN HW, FRANKEL H, BLEVINS WV.

J Appl Physiol. 1954 Apr;6(10):634-44. No abstract available.

PMID:
13162952

Supplemental Content

Loading ...
Support Center